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ORIGINAL ARTICLE
Limited clinical efﬁcacy of azacitidine in transfusion-dependent,
growth factor-resistant, low- and Int-1-risk MDS: Results from the
nordic NMDSG08A phase II trial
M Tobiasson1, I Dybedahl2, MS Holm3, M Karimi4, L Brandefors5, H Garelius6, M Gro¨vdal7, I Ho¨gh-Dufva8, K Grønbæk9, M Jansson4,
C Marcher10, L Nilsson11, AO Kittang12, A Porwit1, L Saft1, L Mo¨llga˚rd1 and E Hellstro¨m-Lindberg1
This prospective phase II study evaluated the efﬁcacy of azacitidine (Aza)þ erythropoietin (Epo) in transfusion-dependent patients
with lower-risk myelodysplastic syndrome (MDS). Patients ineligible for or refractory to full-dose Epoþ granulocyte colony
stimulation factors for48 weeks and a transfusion need ofX4 units over 8 weeks were included. Aza 75mgm 2 d 1, 5/28 days,
was given for six cycles; non-responding patients received another three cycles combined with Epo 60 000 units per week. Primary
end point was transfusion independence (TI). All patients underwent targeted mutational screen for 42 candidate genes. Thirty
enrolled patients received Xone cycle of Aza. Ten patients discontinued the study early, 7 due to adverse events including 2
deaths. Thirty-eight serious adverse events were reported, the most common being infection. Five patients achieved TI after six
cycles and one after Azaþ Epo, giving a total response rate of 20%. Mutational screening revealed a high frequency of recurrent
mutations. Although no single mutation predicted for response, SF3A1 (n¼ 3) and DNMT3A (n¼ 4) were only observed in non-
responders. We conclude that Aza can induce TI in severely anemic MDS patients, but efﬁcacy is limited, toxicity substantial and
most responses of short duration. This treatment cannot be generally recommended in lower-risk MDS. Mutational screening
revealed a high frequency of mutations.
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INTRODUCTION
The myelodysplastic syndromes (MDSs) constitute a group of
malignant hematopoietic stem cell disorders characterized by
pancytopenia, ineffective hematopoiesis, dysplastic bone marrow
changes and a signiﬁcant risk for progression to acute myeloid
leukemia (AML).
Anemia is the dominating symptom in low- and intermediate-1-
risk MDS. Around 50% of these patients respond to growth factor
treatment, that is, erythropoiesis-stimulating agents (ESA)±
granulocyte colony stimulation factors (G-CSF), and the median
duration of response is 2 years.1–4 A predictive model based on
serum levels of erythropoietin (S-Epo) and the red blood cell
transfusion rate was developed to select patients with different
probabilities for response to treatment. Patients with a transfusion
need of X2 red blood cell units per 4 weeks and S-Epo level
4500U l 1 showed only 7% response and were considered not
eligible for this treatment.5 Two large retrospective studies
indicate an improved survival for patients treated with ESA
compared with untreated patients.2,6 Patients not eligible for or
refractory to growth factors require transfusion therapy with
compromised quality of life possibly need for iron chelation
therapy and worse outcome in case of allogeneic stem cell
transplantation.7
In Europe, azacitidine (Aza) is registered for treatment of patients
with higher-risk MDS where it has been shown to prolong survival.8
In the US, the label encompasses all patients with MDS. A subgroup
analysis of patients (n¼ 22) with refractory anemia/refractory
anemia with ringed sideroblast in the pivotal, prospective study
showed complete remission, partial remission and hematological
improvement in 9, 18 and 32%, respectively.9 A second prospective
study reported transfusion independence (TI) after treatment with
Aza in 65% of previously transfusion-dependent (TD) patients
(n¼ 40) with lower-risk MDS.10 Furthermore, two retrospective
studies evaluated the effect of Aza in lower-risk MDS populations.
Musto et al.11 reported complete remission, partial remission and
hematological improvement was 16, 10 and 20%, respectively, and
Prebet et al.12 reported complete remission, partial remission and
hematological improvement was 12, 5 and 25%, respectively. None
of these four studies employed ESA resistance as an inclusion
criterion. Recently, a prospective study treating ESA-resistant
patients with lower-risk MDS with Aza 75mgm 2 per day 1–5
every 28 days showed overall response rate of 47% and
achievement of TI in previously TD patients in 33% of the
patients.13
Mutations in a number of genes have been linked to the MDS
disease, and some of them also with outcome.14 A recent study of
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288 patients with low- and Int-1-risk MDS identiﬁed TET2 (23% of
samples), SF3B1 (22%), U2AF1 (16%), ASXL1 (15%), SRSF2 (15%) and
DNMT3A (13%) as the most commonly mutated genes in a cohort
of lower-risk MDS.15 Early association studies between mutational
status and response to Aza indicate a higher response rate for
TET2-mutated patients and a lower response rate for ASXL1-
mutated patients.16,17
We hypothesized that Aza can induce TI in TD, ESA-resistant
patients with lower-risk MDS and enrolled 30 patients in an
investigator-initiated prospective phase II trial. Aza was assessed
as monotherapy and in combination with ESA. Compared with
previous reports, the overall efﬁcacy of Aza in our study was
limited and toxicity considerable. Targeted sequencing revealed a
high frequency of recurrent gene mutations, most commonly
involving splice factor genes and epigenetic regulators.
SUBJECTS AND METHODS
Study population
Eligible patients should fulﬁll the inclusion criteria: (i) age of 18 years or
more; (ii) MDS with international prognostic score system (IPSS) low or
Int-1, or mixed MDS/myeloproliferative disorder; either CMML with o10%
marrow blasts or refractory anemia with ringed sideroblast-T; (iii) patients
with high or intermediate probability for response according to the
predictive model5 should be refractory to Epo (equivalent toX60 000U of
EPO per week for X8 weeks), followed by EpoþG-CSF for X8 weeks,
biosimilar drugs in equipotent doses or EpoþG-CSF upfront for 8 weeks.
Patients with low probability for response according to the predictive
model5 were eligible without prior Epo/G-CSF treatment. Assessment of
refractoriness was performed at the time of enrollement; (iv) transfusion
rateX4 units over the last 8 weeks orX8 units over the last 26 weeks; (v)
subject had signed the informed consent document; and (vi) men and
women of childbearing potential had to use effective contraception during
and three months after treatment. Exclusion criteria encompassed
eligibility for curative treatment and are listed in Supplementary Table 1.
The trial was approved by the National Ethical committees of Sweden,
Denmark and Norway, conducted in accordance with the Declaration of
Helsinki and registered at www.clinicaltrials.gov: NCT01048034. The Nordic
MDS Group was the sponsor of this trial, for which Celgene provided a research
grant and the study drug Aza, and Roche provided the study drug beta-Epo.
Study protocol is present in Supplementary Data.
Study design
The main objective of this prospective open-label, non-randomized,
multicenter phase II trial was to study the efﬁcacy of Aza to induce TI in
previously TD patients. For this reason, number of patients achieving TI
was chosen as the primary end point. Secondary objectives encompassed
TI on the combination of Azaþ ESA, effect on bone marrow morphology
and biology, peripheral blood parameters, cytogenetics, safety and
response in relation to mutational status. Enrolled patients received six
cycles of Aza, 75mgm 2 for 5 consecutive days every 28 days. Patients
achieving TI terminated the study after six cycles and were subject to
maintenance treatment according to the investigator’s judgement. The
schedule and dosage of the maintenance treatment was designed by the
investigator. Patients still TD after 6 cycles continued with another three
cycles of Aza, with the addition of Epo-b 60 000 units per week. Efﬁcacy
assessment was performed after six cycles (week 28) and nine cycles (week
45). Toxicity, including cytopenias, was graded according to the National
Cancer Institute toxicity criteria (CTC for Adverse Events, version 3.0,
Washington DC, WA, USA). In case of suspected drug-related hematolo-
gical toxicity, the dose of Aza could be lowered according to a pre-deﬁned
scheme. In case of severe hematological toxicity (absolute neutrophil
count (ANC)o0.5 109 l 1 or platelet (Plt)o15 109 l 1) or non-hema-
tological toxicity grade 3 or 4, the next planning cycle was temporarily
discontinued.
Use of G-CSF was allowed during treatment when found appropriate by
the investigator.
Morphology and cytogenetics
Bone marrow morphology, including biopsy for assessment of cellularity
and ﬁbrosis, was performed before inclusion and at week 28 and 45.
Morphological specimens were reviewed centrally according to the
standard procedure of the Nordic MDS group.18 The morphological
assessment included presence of dysplasia, blast count, cellularity and
ﬁbrosis. Metaphase cytogenetic analysis performed within 6 months
before inclusion was used to establish the karyotype. Assessment of
cytogenetic response was performed at week 28 if chromosomal
aberrations were present at inclusion.
Mutational analysis
All the patients registered for this study were analyzed for 42 genes
recurrently mutated in myeloid disorders using high throughput sequen-
cing by Haloplex target enrichment technology (Agilent Technologies,
Sanata Clara, CA, USA), see Supplementary Table 5 for a list of included
genes. In general, CD34þ cells were separated from bone marrow
aspirates pre-treatment by a magnetic activated cell sorting (MACS,
Miltenyi Biotec Norden, Lund, Sweden) as previously described.18 Genomic
DNA was extracted from 1 106 CD34 cells using the Gene Elute
genomic DNA extraction kit (Sigma-Aldrich, Stockholm, Sweden). The
Haloplex target enrichment kit G9901A/B was designed using Halodesign
wizard available by Agilent (http://www.halogenomics.com), 679 target
regions were included with 99.2% coverage of the 42 selected genes. All
samples were individually barcoded during enrichment and samples were
pooled before sequencing using Illumina HiSeQ 2000 system (Illumina,
San Diego, CA, USA). Sequencing reads were mapped over human genome
19 and the variants were called using SAMTOOLS.19 The minimum
coverage to consider in the analysis was 30 and the allele should have a
minimum of 10% of reads. Sequence variations were annotated and
functionally classiﬁed using ANNOVAR.20 Variants previously reported as
germline polymorphisms in 1000 genome and ESP5400 databases were
excluded.21,22 Finally, variants located in non-coding regions as well as
synonymous variants were ﬁltered out.
Response criteria
TI was deﬁned as no need for red blood cell transfusions in combination
with a stable hemoglobin during the 8 weeks preceding evaluation.
Erythroid response was also assessed using the International Working
Group criteria for MDS,23 for example, an absolute reduction of the
transfusion need by X4 units per 8 weeks. In addition, morphological
response, platelet response and neutrophil response were assessed using
the International Working Group criteria.23 Complete cytogenetic response
was deﬁned as normalized karyotype by metaphase cytogenetic analysis
for patients with previous aberrations. Safety was evaluated by monitoring
and recording of adverse events.
Study evaluation and statistics
The study was designed to detect an efﬁcacy ofX20%, deﬁned asX20%
of patients reaching the primary end point. By using Wald’s sequential
probability ratios, we deﬁned the number of treated patients needed to
conclude, with a power of 90% and an alpha error of 5%, that the
treatment was inefﬁcacious, for example, has an efﬁcacy of o20%. If 14
consecutive patients were to fail to respond to treatment, the study was
planned to close for further inclusion.
The response population for Aza as monotherapy was deﬁned as all
patients receiving X1 dose of Aza. In addition, response rate was also
calculated for the patients completing six cycles of Aza. Similarly, the
response population for the combined treatment of Azaþ ESA consisted of
all patients receiving one additional dose of Aza combined with ESA, and
response rates were also calculated for patients completing three cycles of
the combined treatment. The safety population consisted of all included
patients.
Continuous variables were summarized using the mean or median
(range) value depending on distribution of data and frequency tables were
used to summarize categorical variables.
Association between pre-treatment characteristics and response was
assessed using a univariate approach. Statistical methods used were t-test
for normally distributed data, Mann–Whitney U-test for non-normally
distributed data and Fisher’s exact test for categorical data. The sample
size did not allow for multivariate testing.
All statistical calculations were performed using the SPSS 20.0 software
(IBM, New York, NY, USA).
Long-term follow-up
Enrolled patients are evaluated regarding survival, transformation to AML
and subsequent treatment for up to 3 years after inclusion.
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RESULTS
Patient characteristics
Thirty patients from 11 centers were enrolled between January
2010 and September 2011 including 21 men and 9 women with a
median age of 69 years. The most common WHO subclasses were
refractory cytopenia with multilineage dysplasia (n¼ 13) and
refractory cytopenia with multilineage dysplasia-RS (n¼ 5) (see
Table 1 for details). An additional six patients were screen failures.
Median duration of disease was 2 years (range 0–20). Median
number of transfused units of erythrocytes during the 8 and 26
weeks preceding inclusion was 7 (range 4–14) and 16 (range
4–40), respectively. Median bone marrow cellularity and blast
count was 70% (20–100) and 2% (0–9), respectively. Six patients
scored IPSS low, whereas 24 patients scored intermediate-1.
Twenty patients belonged to the favorable IPSS cytogenetic risk
group, whereas 10 patients belonged to the intermediate group.
Eighteen patients were previously treated with ESAþG-CSF
without achieving TI, remaining patients had poor probability of
response according to the predictive model and were considered
refractory upfront. Median Plt and ANC pre-treatment were
210 109 l 1 (range 22–1468) and 1.7 109 l 1 (range
0.3–15.1), respectively. Thrombocytopenia (Plt counto100 109 l 1)
was observed in ﬁve patients, before start of treatment, of which
three patients had Plt counts o30 109 l 1. Neutropenia
(o1.0 109 l 1) was observed in eight patients before start of
treatment including four cases with o0.5 109 l 1. See
Supplementary Table 4 for characteristics of each patient.
Frequency of mutations
Sequencing was performed in 27 patients of whom 24 had one or
more mutations (Figure 1). Of the three patients without
mutations, two had a chromosomal aberration. Hence, 96% of
the patients had at least one clonal marker. A total number of 53
mutations were identiﬁed and the median number of mutations
per patient was 2 (range 0–5). Nineteen and 17 patients had a
mutation involving a splice factor gene or an epigenetic regulator,
respectively. Two and four patients had mutations in more than
one splice factor gene and epigenetic regulator, respectively. The
most frequently mutated genes were SF3B1 (n¼ 11), ASXL1 (n¼ 9)
and TET2 (n¼ 7). All patients with refractory anemia with ringed
sideroblast or refractory cytopenia with multilineage dysplasia-RS
(n¼ 7) had a mutated SF3B1; three and two patients had a
concomitant TET2 and DNMT3A mutation, respectively. The
number of mutations did not correlate with disease duration
(P¼ 0.157). See ﬁgure 1 and Supplementary Table 2 for detailed
information.
Treatment results
Thirty patients received X1 cycle of Aza and 22 of these
completed the initial six cycles of Aza as monotherapy. Eight
patients pre-terminated the treatment after cycle 1 (n¼ 1), cycle 2
(n¼ 2), cycle 3 (n¼ 3) and cycle 5 (n¼ 2). Sixteen patients
continued with the combined treatment of Azaþ ESA, 15 of which
completed the three additional cycles. Of 30 patients receiving
X1 cycle of Aza as monotherapy, 5 (17%) achieved TI. Of the 16
patients receivingX1 cycle of the combined treatment, 1 additive
patient (6%) achieved TI. Response rates for patients completing
all cycles of monotherapy and combined treatment were 5/22
(23%) and 1/15 (7%), respectively. An illustration of outcome for
included patients is given in Figure 2a.
Three patients achieved an erythroid improvement (reduced
transfusion requirement) in accordance to the International
Working Group criteria, two on monotherapy and one on
combined treatment. Hence, the total erythroid response rate
was 9 of 30 (30%).
Four patients had an elevated blast count before treatment;
three of these were evaluated after treatment, in which all three
patients normalized their blast count. Only one of these patients
achieved TI. Complete cytogenetic response was observed in one
of seven evaluated patients, a patient with trisomy 8 who also
achieved TI. Platelet response was not observed in any of the ﬁve
patients with pre-treatment platelet count o100 109 l 1.
Neutrophil response was observed in one of eight patients with
pre-treatment neutrophil count o1.0 109 l 1. This patient also
achieved TI.
Duration of response for the six responding patients was o6
months for four patients; one patient responded for 24 months
and one patient is still responding after 21 months. Both long-
term responders and one of the short-term responders were
exposed to Aza given as maintenance treatment. Median number
of cycles until TI was 3½. Duration of response for the three
patients with hematologic improvement without complete TI was
2, 3 and 8 months, respectively. See Table 2 for details regarding
responding patients.
Markers for response to treatment
Disease duration was signiﬁcantly associated with response;
responding patients had a shorter median disease duration
compared with non-responders (0.5 vs 2 years, P¼ 0.013).
Unexpectedly, the six responders showed a higher median
transfusion rate before treatment compared with non-respon-
ders (8.5 (range 4–10) vs 6 units (range 4–14), P¼ 0.038).
Moreover, all six patients had IPSS Int-1-risk MDS, whereas no
IPSS low-risk patients responded. No other parameters such as
morphology, karyotype, blood test including iron status and
mutational status were associated with a response. Two of six
responding patients had trisomy 8 compared with one of 24
non-responding patients.
TET2 was mutated in two (33%) of the responding (n¼ 6)
patients compared with ﬁve (28%) of the non-responding (n¼ 21)
Table 1. Patient characteristics
Median (range) age 69 years (55–80)
Gender (M/F) 21/9
Median (range) duration of disease 2 years (0–20)
Median transfusion units needed q 8 weeks 7 units (4–14)
WHO classification, n
RA/RARS/RCUD 1/2/2
RCMD/RCMD-RS 13/5
RAEB-I/MDS 5q- 3/1
MDS/MPD unclassified 3
Significant fibrosis (gradeX2), n 4
Median (range) cell percentage 70% (20–100)
Median (range) blast count 2% (0–9)
IPSS, low/Int-1, n 6/24
WPSS, low/Int/high, n 3/14/13
IPSS-R, low/intermediate, n 15/15
IPSS cytogenetics, n 20/10/0
Favorable/intermediate/adverse
Median (range) S-erythropoietin 443U l 1 (25–2313)
Median(range) S-ferritin 1891 mg l 1 (220–6230)
Median (range) ANC count 1.7 109 l 1 (0.3–15.1)
Median (range) platelet count 210 109 l 1 (22–1468)
Median (range) number of mutations 2 (0–5)
Patients with a mutation in an epigenetic regulator 18
Patients with a mutation in a splice factor gene 19
Abbreviations: ANC, absolute neutrophil count; F, female; IPSS, international
prognostic score system; MDS, myelodysplastic syndrome; M, male; MPD,
myeloproliferative disorder; RA, refractory anemia; RAEB-I, RA with excess of
blasts; RARS, RA with ringed sideroblast; RCMD, refractory cytopenia with
multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblast; RCUD,
refractory cytopenia with unilineage dysplasia; S, serum; WHO, world health
organization; WPSS, WHO-based prognostic score system.
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patients (P¼ 0.633). ASXL1 was mutated in three (50%) and six
(29%) of the responding and non-responding patients, respec-
tively (P¼ 0.367). Although none of the mutations were signiﬁ-
cantly associated with response to treatment, certain mutations
including DNMT3A (n¼ 4) and SF3A1 (n¼ 3) were only observed in
non-responders. See Table 3 for a list of all tested variables.
Long-term outcome
Twelve patients have died during or after the study after a median
follow-up of 30 months. Median survival is still not reached. Three
patients (10%) transformed to AML during the follow-up period at
11, 13 and 27 months. See ﬁgure 2 for Kaplan–Meier estimation of
survival and leukemic progression. Hence, survival and
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RUNX1
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Figure 1. Illustration of mutational and cytogenetic status for included patients.
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Figure 2. (a) Outcome after azacitidine as monotherapy and the combined treatment of azacitidine and erythropoietin (Epo). Response is
defined as transfusion independence. (b) Duration of response. (c) Overall survival. (d) Leukemic transformation.
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transformation rates were similar to what would be expected from
an Int-1-risk cohort.
Safety evaluation
Ten patients pre-terminated the study: 5 due to sustained
neutropenia or thrombocytopenia, 2 due to death, 2 due to
patient’s wish and 1 due to investigators’ choice. No patient
progressed to AML during the study. Dose reduction of Aza was
needed in 11 patients. Ten patients had a temporary discontinua-
tion of Aza of more than 1 week’s duration.
The most important hematological toxicity was neutropenia.
Nineteen patients suffered from severe neutropenia
(ANCp0.5 109 l 1) at any time point during treatment, 4 of
which were severely neutropenic before the treatment was
started. Similarly, 11 patients suffered from severe thrombocyto-
penia (Pltp30 109 l 1) during treatment, of which 3 were
severely thrombocytopenic before start of treatment. No severe
bleeding was reported in the study. Nadir values after a cycle of
Aza were seen at week 3 for thrombocytes (median 115 109 l 1)
and at week 4 for neutrophils (median 1.1 109 l 1), respectively.
The most commonly reported non-hematological adverse
events were infection (n¼ 30) and the related adverse events
were neutropenic fever (n¼ 12) and fever (n¼ 6). Other frequent
non-hematological adverse events were injection-site reaction
(n¼ 14) and constipation (n¼ 15). Two patients experienced atrial
ﬁbrillation and one ventricular tachycardia. No serious unexpected
toxicity was observed.
Thirty-eight serious adverse events were reported in 18 patients
during the study period. The main serious adverse event criterion
(n¼ 36) was in-patient hospitalization. The vast majority (n¼ 28)
of the serious adverse event were related to infection with or
without neutropenia. A complete list of all reported hematological
and non-hematological adverse events is enclosed in Table 4 and
Supplementary Table 3.
Cause of death for the ﬁrst patient is unknown; the patient
suffered a sudden death after two cycles of Aza and had a
moderate cytopenia before start of treatment, which was
aggravated during treatment. Cause of death for the second
patient was septicemia with Escherichia coli during Aza-associated
severe neutropenia.
Ten patients received G-CSF due to neutropenia during the
study with a median ANC level of 0.3 109 l 1 (range 0.1–1–5)
when G-CSF was started.
DISCUSSION
This prospective study evaluated the efﬁcacy of Aza in a
population of selected ESA-resistant, TD patients with lower-risk
MDS. It is an important study as Aza is used in clinical practice for
lower-risk patients, as demonstrated recently by data from the
French compassionate program. However, previous clinical trials
of Aza in lower-risk patients have not speciﬁcally targeted
Epo-/G-CSF-resistant cohorts. Patients enrolled in the present trial
had a severe transfusion need, reﬂected in a high median transfusion
Table 2. Characteristics of responding patients
UPN SE07 SE31 SE35 DK14 DK34 SE22
Age 72 74 78 64 69 73
Gender Male Female Female Male Male Male
Year of diagnosis 2010 2010 2011 2009 2010 2010
Prior MDS treatment EPOþG-CSF EPOþG-CSF EPO EPO None EPOþG-CSF
Morphology WHO
Before RCMD-RS RCMD RCMD RCUD RCMD RAEB-I
After RCMD-RS RCMD RCMD NA RCMD RCMD
Blasts
Before 4 1 2 3 4 9
After 1 2 4 NA 2 3
Cell percentage
Before 70 70 90 NA 50 70
After 40 40 80 NA 30 80
Mutations ASXL1 PRPF40B ASXL1 SRSF2 ASXL1 TP53
SF3B1 RUNX1 SRSF2 U2AF1 U2AF1
TET2 SF3B1 STAG2
TET2
IPSS Int-1 Int-1 Int-1 Int-1 Int-1 Int-1
WPSS High High High Intermed High High
Transfusion units per 8 weeks 10 4 9 10 8 8
Cytogenetics
Before del(20q) Trisomy 8 Trisomy 8 Normal Normal del 5q, t(12;18)
After del(20q) normal Trisomy 8 NA NA NA
Cycles until TI 6 3 4 2 3 9
Response duration 3 months 421 months 3 months 24 months 5 months 5 months
Total numbers of cycles given 6 418 6 20 11 9
Transformation No No No No No No
Death No No No No No After study
Abbreviations: EPO, erythropoietin; G-CSF, granulocyte colony stimulating factor; IPSS, international prognostic score system; MDS, myelodysplastic syndrome;
NA, not applicable; RAEB-I, refractory anemia with excess of blasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed
sideroblast; RCUD, refractory cytopenia with unilineage dysplasia; TI, transfusion independence; UPN, unique patient number; WHO, world health
organization; WPSS, WHO-based prognostic score system.
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demand before inclusion and a high median ferritin level.
This study shows a lower response rate in terms of TI compared
with previous reports. Moreover, only 2 of 30 patients showed
responses lasting more than 6 months. The recent report by Fili
et al.13 assessed Aza in a similar cohort of patients, however, that
cohort included also non-TD patients, patients with a lower
transfusion rate and enrolled patients who did not have the same
degree of documented resistance against the combined EPO/
G-CSF treatment. Fili et al. found an overall response rate of 47%,
although only 27% of previously TD patients achieved TI. The
response rate in our study is lower than that of previous reports,
possibly due to the careful selection of documented ESA-/G-CSF-
resistant patients.
Toxicity and most importantly neutropenia with associated
infections were substantial in this study. The marked suppression
of ANC and Plt counts observed during treatment cycles likely
reﬂects a cytotoxic effect on the hematopoiesis. Most studies on
lower-risk MDS have used the same Aza dose, 75mgm 2 V,
which makes suboptimal dosing a less likely.
Interestingly, long-term follow-up demonstrated survival times
and AML transformation rates as expected according to the risk
proﬁle (IPSS-R and WPSS, WHO-based prognostic score system) of
the cohort. After a median follow-up of 30 months, median
survival was reached neither for all included patients nor for non-
responding patients. This is in contrast to previous reports on
survival after Aza failure in lower-risk MDS: 15 months (n¼ 59) and
17 months (n¼ 423).12,24 Moreover, only three patients
transformed to AML during follow-up, which makes non-
leukemic death the major cause of death for these patients.
From a biological point of view, our cohort is thus characterized by
a highly ineffective erythropoiesis but with a relatively low
propensity of transformation to more advanced MDS.
No individual morphological, cytogenetic or genetic parameter
was signiﬁcantly associated with response to treatment. Larger
studies will be needed to further assess potential biomarkers.
Interestingly, two out of three patients with trisomy 8 responded;
a favorable response rate for trisomy 8 patients has previously
been reported in higher-risk MDS.25
Recurrent mutations were found in all but three sequenced
patients, rendering this lower-risk cohort a mutational frequency
at least as high as in previous reports on MDS of all risk
groups.14,15,26,27 A majority of the patients carried a mutation in a
splice factor gene and/or in one or several of the genes involved
in epigenetic regulation. None of the mutations predicted for a
response to treatment. Notably, mutations in two genes DNMT3A
Table 3. Statistical association between response and pre-treatment characteristics
Variable Units Responders n¼ 6 Non-responders n¼ 24 P-value
Age, mean (s.d.) Years 71.5 (5.01) 68.29 (7.21) 0.231
Disease duration, median (range) Years 0.5 (0–1) 2 (0–20) 0.013
S-ferritin, median (range) gml 1 1962 (1210–2455) 1842 (220–6230) 0.836
S-erythropoietin, median (range) Uml 1 664 (59–1041) 244 (25–2313) 0.755
Blast counts, median (range) Percentage 3.5 (1–9) 1 (0–8) 0.054
Cell percentage, median (range) Percentage 70 (50–90) 70 (20–100) 0.908
Transfused units last 8 weeks, median (range) Units of RBC 8.5 (4–10) 6 (4–14) 0.038
Transfused units last 26 weeks, median (range) Units of RBC 16 (8–26) 16 (4–40) 0.193
Number of mutations, median (range) 2.5 (1–4) 2 (0–5) 0.157
Gender, n (%) 1
Male 4 (67) 17 (71)
Female 2 (33) 7 (29)
IPSS, n (%) 0.302
Low 0 6 (25)
Intermediate-1 6 (100) 18 (75)
Cytogenetics IPSS, n (%) 0.141
Favorable 2 (33) 18 (75)
Intermediate 4 (67) 6 (25)
Mutation in epigenetic regulator, n (%) 4 of 6 (67) 14 of 21 (67) 1
Splice factor mutation, n (%) 6 of 6 (100) 13 of 21 (62) 0.136
TET2 mutation, n (%) 2 of 6 (33) 5 of 21 (24) 0.633
ASXL1 mutation, n (%) 3 of 6 (50) 6 of 21 (29) 0.367
DNMT3A mutation, n (%) 0 of 6 (0) 4 of 21 (19) 0.545
SF3A1 mutation, n (%) 0 of 6 (0) 3 of 21 (14) 1
Abbreviations: IPSS, international prognostic score system; RBC red blood cells; S, serum level.
Table 4. Reported adverse events, grade 3–4
Number of
adverse events
Number of
patients
Hematological anemia
Thrombocytopenia 1 1
Neutropenia 32 11
Pancytopenia 1 1
Non-hematological anemia
Cardiac arrythmia 3 3
Chest pain 1 1
Constipation 1 1
Dyspnea 1 1
Fever 4 1
Neutropenic fever 12 4
Increased ferritin 1 1
Infection 14 7
Heart valve defect 1 1
Obstruction of urethra 1 1
Sudden death 1 1
Syncope 1 1
Total 75
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(n¼ 4) and SF3A1 (n¼ 3) were only observed in non-responders,
which deserve further investigation. The genomes of AML patients
with DNMT3A mutations have previously been reported to be
hypomethylated, which might explain why treatment with Aza is
ineffective.28 These data differ to some extent from the
preliminary reported data from Bejar et al.,17 showing a higher
response rate for TET2-mutated patients and a lower response rate
for ASXL1-mutated patients with low- and high-risk MDS. This
discrepancy supports the need for much larger datasets to reach
conclusive interpretations. In addition, the sharper response
criteria, TI, used in this study may have contributed to the
observed pattern.
We conclude that Aza can induce TI in a minor proportion of
ESA-refractory lower-risk MDS patients, but that the efﬁcacy
overall is low with few long-lasting responses. Moreover, toxicity
is signiﬁcant with potentially deleterious outcome. Hence, Aza
cannot be recommended as standard treatment for these
patients and does not seem to synergize with ESA. It is possible
that molecular analysis to some extent may assist in the
decision making for this patient cohort. However, larger studies
are needed to evaluate the impact of mutational status on
response rate.
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